News

BioSpace6h
Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg
With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...
STAT2d
Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows
The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...
Fierce Biotech6h
ASCO’s bubble of hope: Execs focus on ‘rewriting textbooks’ in cancer care at conference
The first half of this year been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...
BioSpace6h
FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More
Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...
Merck, Daiichi pull US application for 'guided missile' drug for lung cancer
Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...
BioPharma Dive4d
Merck, Daiichi pull approval application for ADC in lung cancer
A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...
Medscape7h
Adjuvant Nivolumab + CRT Improves Disease-Free Survival in Head and Neck Cancer
Postoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.” ...
Merck, Daiichi Sankyo pull marketing application for lung cancer therapy
Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...
Merck, Daiichi pull US application for 'guided missile' therapy for lung cancer
Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...